Milestone Pharma leaps on positive Phase III results for etripamil

17 October 2022
milestone-large

Canadian drug developer Milestone Pharmaceuticals (Nasdaq: MIST) today announced positive top-line efficacy and safety data from the Phase III RAPID clinical trial of etripamil, sending the firm’s shares up almost 30% $8.49 in pre-market trading in New York.

The drug is the company's investigational calcium channel blocker, intended for patients with paroxysmal supraventricular tachycardia (PSVT), which a couple of years ago did not achieve its primary endpoint in the NODE-301 Phase III study.

The trial met its primary endpoint, with 64.3% of patients self-administering etripamil converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p<0.001).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical